|Bid||221.53 x 1000|
|Ask||221.63 x 900|
|Day's range||221.03 - 225.28|
|52-week range||177.05 - 264.97|
|Beta (5Y monthly)||0.81|
|PE ratio (TTM)||17.87|
|Earnings date||28 Jan 2021 - 01 Feb 2021|
|Forward dividend & yield||6.40 (2.85%)|
|Ex-dividend date||13 Nov 2020|
|1y target est||252.54|
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pipeline and regulatory updates take centerstage in the biotech sector as Regeneron (REGN) and Gilead Sciences (GILD), among others, provide updates on their pipeline candidates.
Amgen (AMGN) will terminate the collaboration with Cytokinetics and transition development and commercialization rights for omecamtiv mecarbil and AMG 594 to the latter.